348 related articles for article (PubMed ID: 30896772)
1. Outcomes Associated With Sustained-Release Intraocular Fluocinolone Implants in a Case of Melanoma-Associated Retinopathy Treated Without Systemic Immunosuppression.
Karatsai E; Robson AG; Taylor SRJ
JAMA Ophthalmol; 2019 May; 137(5):564-567. PubMed ID: 30896772
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of fluocinolone acetonide intravitreal implant (0.59 mg) in birdshot retinochoroidopathy.
Bajwa A; Aziz K; Foster CS
Retina; 2014 Nov; 34(11):2259-68. PubMed ID: 24999722
[TBL] [Abstract][Full Text] [Related]
3. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis.
Jaffe GJ; Ben-Nun J; Guo H; Dunn JP; Ashton P
Ophthalmology; 2000 Nov; 107(11):2024-33. PubMed ID: 11054326
[TBL] [Abstract][Full Text] [Related]
4. Melanoma-associated retinopathy during pembrolizumab treatment probably controlled by intravitreal injections of dexamethasone.
Poujade L; Samaran Q; Mura F; Guillot B; Meunier I; Du-Thanh A
Doc Ophthalmol; 2021 Apr; 142(2):257-263. PubMed ID: 32975694
[TBL] [Abstract][Full Text] [Related]
5. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE
Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715
[TBL] [Abstract][Full Text] [Related]
6. BILATERAL INTRAVITREAL 0.19-MG FLUOCINOLONE ACETONIDE IMPLANT FOR PERSISTENT NONDIABETIC CYSTOID MACULAR EDEMA AFTER VITRECTOMY.
Ong SS; Walter SD; Chen X; Thomas AS; Finn AP; Fekrat S
Retin Cases Brief Rep; 2021 May; 15(3):261-265. PubMed ID: 30015770
[TBL] [Abstract][Full Text] [Related]
7. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results.
Ramchandran RS; Fekrat S; Stinnett SS; Jaffe GJ
Am J Ophthalmol; 2008 Aug; 146(2):285-291. PubMed ID: 18533125
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies to transient receptor potential cation channel, subfamily M, member 1 in a Japanese patient with melanoma-associated retinopathy.
Morita Y; Kimura K; Fujitsu Y; Enomoto A; Ueno S; Kondo M; Sonoda KH
Jpn J Ophthalmol; 2014 Mar; 58(2):166-71. PubMed ID: 24468869
[TBL] [Abstract][Full Text] [Related]
9. Melanoma-associated retinopathy treated with ipilimumab therapy.
Audemard A; de Raucourt S; Miocque S; Comoz F; Giraud JM; Dreno B; Bienvenu B; Rogerie MJ; Dompmartin A
Dermatology; 2013; 227(2):146-9. PubMed ID: 24051549
[TBL] [Abstract][Full Text] [Related]
10. [Case report of melanoma-associated retinopathy associated with positive auto-antibodies against retinal bipolar cells].
Hanaya J; Nakamura Y; Nejima R; Miyata K; Mera K; Ohguro H; Yamamoto S
Nippon Ganka Gakkai Zasshi; 2011 Jun; 115(6):541-6. PubMed ID: 21735759
[TBL] [Abstract][Full Text] [Related]
11. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroid treatment for melanoma-associated retinopathy: effect on visual acuity and electrophysiologic findings.
Jacobzone C; Cochard-Marianowski C; Kupfer I; Bettembourg S; Dordain Y; Misery L; Cochener B; Sassolas B
Arch Dermatol; 2004 Oct; 140(10):1258-61. PubMed ID: 15492190
[TBL] [Abstract][Full Text] [Related]
13. Electroretinographic Findings in Melanoma-Associated Retinopathy Treated by Intravitreal Dexamethasone Implant.
Abou-Samra A; Tzekov R; Yannuzzi NA; Tarabishy AB
Ophthalmic Surg Lasers Imaging Retina; 2021 Aug; 52(8):454-456. PubMed ID: 34410186
[TBL] [Abstract][Full Text] [Related]
14. Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis.
Chieh JJ; Carlson AN; Jaffe GJ
Am J Ophthalmol; 2008 Oct; 146(4):589-594. PubMed ID: 18639220
[TBL] [Abstract][Full Text] [Related]
15. Node way out.
Vaphiades MS; Brown H; Whitcup SM
Surv Ophthalmol; 2000; 45(1):77-83. PubMed ID: 10946083
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of birdshot chorioretinopathy treated with an intravitreal sustained-release fluocinolone acetonide-containing device.
Rush RB; Goldstein DA; Callanan DG; Meghpara B; Feuer WJ; Davis JL
Am J Ophthalmol; 2011 Apr; 151(4):630-6. PubMed ID: 21277557
[TBL] [Abstract][Full Text] [Related]
17. Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.
; Kempen JH; Altaweel MM; Holbrook JT; Sugar EA; Thorne JE; Jabs DA
JAMA; 2017 May; 317(19):1993-2005. PubMed ID: 28477440
[TBL] [Abstract][Full Text] [Related]
18. SD-OCT pattern of retinal venous occlusion with cystoid macular edema treated with Ozurdex®.
Coscas G; Coscas F; Zucchiatti I; Glacet-Bernard A; Soubrane G; Souïed E
Eur J Ophthalmol; 2011; 21(5):631-6. PubMed ID: 21500185
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases.
Keltner JL; Thirkill CE; Yip PT
J Neuroophthalmol; 2001 Sep; 21(3):173-87. PubMed ID: 11725182
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants.
Yang Y; Bailey C; Holz FG; Eter N; Weber M; Baker C; Kiss S; Menchini U; Ruiz Moreno JM; Dugel P; Lotery A;
Eye (Lond); 2015 Sep; 29(9):1173-80. PubMed ID: 26113503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
